
Learn About Our Key
Near-Term Milestones
Top line results expected in Q4 2023 for our phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy‑related diarrhea.
We are supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024.


Learn About Our Key Near-Term Milestones
Top line results expected in Q4 2023 for our phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy‑related diarrhea.
We are supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024.